Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038883 · ClinicalTrials.gov registry record · NA
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT00038883: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00038883 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038883, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Interventions
- DRUG Campath-1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2001-04-09 |
| Est. Completion | 2006-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038883
The ClinicalTrials.gov registry entry for NCT00038883 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Campath-1H is the first listed.
NCT00038883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038883 about?
NCT00038883 is a clinical study titled "Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies". High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive...
What is the current status of trial NCT00038883?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2001-04-09. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00038883?
The interventions under investigation include: Campath-1H (DRUG).
Who is sponsoring clinical trial NCT00038883?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.